GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg19-10-2020
19-10-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0550 Name of the Signatory :- HARISH KUBERDesignation :- Company Secretary and Compliance Officer14-10-2020
Glenmark launches medicine for pulmonary fibrosis at Rs 4,500 per month
The indicated price is for treatment using the drug for about a month, or a treatment cycle depending on the disease progression and patient condition14-10-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark introduces NINDANIB (Nintedanib) and is amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India14-10-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September, 2020
Certificate from Practicing Company Secretary under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September, 202012-10-2020
Smaller pharma firms post faster domestic sales growth in September
Barring Cipla and Glenmark, whose sales have grown in double digits due to demand for their Covid-19 drugs like favipiravir, tocilizumab, most big players have posted tepid growth11-10-2020
Glenmark's antiviral combination for moderate Covid-19 shows no benefit
The trial's findings confirm that the addition of umifenovir does not show any incremental benefit in clinical outcomes, the company said09-10-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
No significant clinical benefit with Umifenovir addition in COVID-19 treatment: Glenmark clinical study09-10-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September, 2020
Compliance Certificate under Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September, 202007-10-2020
Glenmark Pharma gets USFDA nod to market drug for relapsing multiple sclerosis
The approved product is a generic version of Biogen Inc's Tecfidera delayed-release capsules.07-10-2020